Пошук академічних текстів

Інформація × Реєстраційний номер 2117U005736, Матеріали видань та локальних репозитаріїв Категорія Стаття Назва роботи Interstitial HDR brachytherapy at non-melanoma skin cancer Автор Дата публікації 01-12-2017 Постачальник інформації Національний медичний університет імені О. О. Богомольця Першоджерело http://ir.librarynmu.com/handle/123456789/411 Видання The Archive of RS Global Publishing / №12(28), December 2017 WORLD Science Опис Conclusions. Thus, the fractionation regime of 8 Gy 2 times a week, totaling 4 fractions, allows achieving a good local control of the primary tumor process. At the same time, the patient's state of health between fractions improves significantly; the probability of infection joining during treatment is reduced. During the study period, no radiation complications were observed in this fractionation regime. Despite a large number of recommendations for the installation of applicators with high-power brachytherapy, there are many controversial questions regarding the choice and placement of applicators, normalization and dose selection. Has been made an assessment the effectiveness of interstitial HDR brachytherapy under irradiation regimen of 32 Gy for 4 fractions when dosing twice a week. 46 patients with histologically confirmed non-melanoma skin cancer other localization were irradiated with MicroSelectron (radioactive source 192Ir) using interstitial HDR brachytherapy. The single focal dose was 8 Gy. The irradiation sessions were carried out 2 times a week, in total 4 fractions. The planning of the treatment process was carried out under 3D CT control. In five years of follow-up after the completion of the full course of interstitial HDR brachytherapy, 96 % of patients had complete regression of the primary tumor process and no radiation complications were observed, and 4 % had local relapses at an average of 18 months after treatment. Thus, the fractionation regime of 8 Gy 2 times a week, totaling 4 fractions, allows achieving a good local control of the primary tumor process. During the study period, no radiation complications were observed in this fractionation regime. Додано в НРАТ 2025-07-17 Закрити